Brian Stolz, senior vice president of neurology, dentistry, and genetics at Valeant Pharmaceuticals International Inc. , has resigned, the company said in a late Friday filing. Stolz left to “pursue other opportunities” and the resignation is effective May 30, the company said. Shares of Valeant rose 0.2% in late trading Friday after ending the regular session up 4.6%. Valeant got a new CEO last month when Joseph Papa resigned as CEO of Perrigo Company plc to take on the job at Valeant. Valeant has been under fire over its accounting practices and drug pricing strategy, and shares are down 73% so far this year and 88% in the past 12 months.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News